India Malaria Vaccine Market By Vaccine Type (Pre-Erythrocytic, Erythrocytic, Multi-antigen, Others), By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Overview

India Malaria Vaccine Market was valued at USD 38.21 Million in 2024 and is expected to reach USD 47.21 Million by 2030 with a CAGR of 3.59% during the forecast period.

The Rising awareness among people for early detection and treatments, coupled with the rising number of people suffering from malaria, is expected to augment the growth of the India malaria vaccine market. Malaria is caused by a parasite called Plasmodium, which is transmitted to humans through the bites of infected mosquitoes. Malaria is preventable and treatable, but the development of effective vaccines is essential to control and ultimately eliminate this disease.

Growing incidences of malaria in the country are a major factor, which is surging the demand for effective malaria vaccines. These malaria vaccines are designed to prevent or reduce the severity of malaria, a disease caused by parasites that are transmitted to humans through the bites of infected mosquitoes. Furthermore, there are various other factors that support the growth of India's malaria vaccine market, such as growing government initiatives, affordable vaccines, rising advancements in biotechnology, and others.

Key Market Drivers

Rise in Occurrences of Malaria

The rising number of malaria cases in India is a key driver of malaria vaccine demand. Malaria continues to be a major public health concern, affecting millions of people each year, especially in rural and economically disadvantaged areas. Despite ongoing efforts in diagnosis, treatment, and vector control, the country still faces high rates of infection, making the need for effective preventive vaccines more urgent than ever.

An effective malaria vaccine could drastically reduce the disease burden and prevent severe infections among vulnerable groups such as children under five and pregnant women. This would help lower both morbidity and mortality rates while improving overall community health in malaria-endemic regions.

According to the World Health Organization (WHO), India accounted for nearly 3% of global malaria cases in 2019, with an estimated 247 million cases worldwide. The highest prevalence is found in Odisha, Chhattisgarh, Jharkhand, and the northeastern states, where poor sanitation and limited healthcare access contribute to persistent outbreaks. The increasing incidence of malaria is expected to drive rapid growth in India’s malaria vaccine market in the coming years.

Increasing Government Support

Strong government support is fueling the growth of India’s malaria vaccine market. Recognizing malaria as a major health threat, the Indian government has launched various initiatives to promote prevention, control, and awareness. Several national campaigns aim to educate communities and encourage active participation in maintaining clean and mosquito-free environments.

In 2022, the Ministry of Health and Family Welfare launched the “Jan Abhiyaans with Jan Bhaagidari” campaign to encourage community involvement in vector control and malaria prevention. Such programs highlight the government’s commitment to eliminating malaria through public engagement and preventive action.

Moreover, the government has strengthened research and development efforts to accelerate malaria vaccine innovation. Policies supporting local vaccine manufacturing have attracted significant investments and fostered a strong domestic vaccine production ecosystem. This proactive approach is creating a favorable environment for pharmaceutical growth, ensuring India remains a key player in global malaria vaccine development and supply.

Download Free Sample Report

Key Market Challenges

Regulatory and Approval Challenges

One of the key challenges in India’s malaria vaccine market is the lengthy regulatory approval process. Malaria transmission in India has reduced by nearly 80% between 2015 and 2023, with the Annual Parasite Index (API) at 0.18 in 2023, classifying it as a low-transmission setting. This complicates vaccine evaluation, as most candidates are designed for high-transmission regions. Unlike Africa, where Plasmodium falciparum dominates, India faces significant transmission of both P. falciparum and P. vivax, with P. vivax accounting for about 35% of cases. Current WHO-endorsed vaccines target only P. falciparum, limiting their fit for India.

The absence of a streamlined regulatory framework delays vaccine distribution, while gaps in public health infrastructure hinder large-scale trials and data collection. The success of malaria control programs makes it harder to conduct efficacy trials locally. The Indian Council of Medical Research (ICMR) is developing AdFalciVax, but deployment is estimated to be 6-7 years away. Variations in vaccine efficacy also remain a concern. RTS, S and R21 vaccines target children under five, who represent about 80% of malaria deaths in Africa, but in India, this group accounts for only 5-20% of cases, as older individuals carry most of the burden. The R21 vaccine showed 75% efficacy in African trials, yet its effectiveness in India still needs to be proven through local trials.

Distribution and Accessibility Issues

Another significant challenge facing the malaria vaccine market in India is the distribution and accessibility of the vaccine, especially in rural and remote regions. Despite India’s progress in healthcare, a large portion of its population still lives in areas where access to healthcare facilities is limited, making it difficult to implement widespread vaccination campaigns. The cold chain logistics required for storing and transporting vaccines, especially in regions with inadequate infrastructure, further exacerbate the issue.

Moreover, the affordability of malaria vaccines is a critical concern, as many rural populations may not have the financial means to access vaccines, particularly in areas with high malaria burden. Government health initiatives and collaborations with international organizations like the World Health Organization (WHO) are crucial to overcoming these barriers, but challenges in funding, distribution networks, and local health system capacities still persist. Ensuring equitable access to malaria vaccines across all regions of India remains a complex task that requires overcoming both logistical and economic hurdles.

Key Market Trends

Growing Awareness About the Importance of Malaria Treatment

Growing awareness among people about the importance of malaria treatment is a significant factor that can contribute to the growth of the India malaria vaccine market. In recent years, public awareness has been bolstered by government initiatives like the National Framework for Malaria Elimination (NFME) 2016–2030, which have led to an 80.5% decline in malaria cases between 2015 and 2023. This success, which includes India exiting the WHO's High Burden to High Impact (HBHI) group in 2024, has increased the demand for effective malaria control tools, including vaccines. As more people become aware of the importance of prevention and treatment, the drive for a vaccine-based solution is expected to intensify.

This growing awareness is also creating a favorable environment for investment in malaria vaccine research and development. Investors and stakeholders recognize the potential demand, which is likely to drive further investment. For instance, Bharat Biotech has invested over $200 million in manufacturing facilities and technology transfers for the RTS,S malaria vaccine. Concurrently, the Indian Council of Medical Research (ICMR) is developing its own indigenous multi-stage malaria vaccine called AdFalciVax. Furthermore, this awareness creates a demand for affordable and effective malaria vaccines, which is particularly significant in India where access to healthcare can be limited in rural areas. To address this, Bharat Biotech has committed to reducing the price of the RTS,S vaccine to less than $5 per dose by 2028, a move made possible through partnerships and process improvements. Affordable and effective vaccines can help reduce the malaria burden and improve healthcare access for vulnerable populations.

Growing Research & Development Activities

Research and development (R&D) are a crucial factor that can significantly contribute to the growth of the India vaccine market. In recent years, there has been a significant increase in R&D investment in India, with the government implementing several initiatives to promote innovation in healthcare. For example, the Department of Pharmaceuticals' "Promotion of Research and Innovation in Pharma-MedTech Sector (PRIP)" scheme has an approved outlay of ₹5,000 crore to support around 300 projects, specifically targeting strategic areas like vaccine-preventable and tropical vector-borne diseases. The increasing focus on R&D has created a favorable environment for vaccine development, with several Indian research institutions working on malaria vaccines.

The availability of a skilled workforce and world-class research institutions has also contributed to the growth of the R&D sector. The Indian Council of Medical Research (ICMR), in partnership with the Department of Biotechnology-National Institute of Immunology (DBT-NII) and the National Institute of Malaria Research (NIMR), is developing a novel indigenous malaria vaccine candidate called AdFalciVax. This multi-stage vaccine targets two critical stages of the Plasmodium falciparum parasite to prevent infection and reduce community transmission.

This innovative approach offers broader protection and the potential for long-term immunity, and the vaccine has shown extended thermal stability, remaining functional for over nine months at room temperature. Through this research, scientists can gain a better understanding of the parasite's biology, which can lead to the development of effective malaria vaccines. Therefore, these increasing R&D activities are expected to support the growth of the India malaria vaccine market in the forthcoming years.

Segmental Insights

Route of Administration Insights

Based on the route of administration, the intramuscular category is currently dominating the India malaria vaccine market due to several key advantages it offers in terms of efficacy, ease of administration, and acceptance among healthcare professionals. Intramuscular injections allow for better absorption of vaccines compared to subcutaneous or oral routes, which is crucial for ensuring a robust immune response, especially for complex vaccines like those targeting malaria.

In addition, the intramuscular route is familiar to healthcare providers across India, making it easier to implement at scale. IM injections are also widely used in existing vaccination programs, providing a sense of standardization that helps ensure smooth integration into national immunization efforts. As malaria vaccination campaigns continue to expand, the familiarity and simplicity of administering vaccines via the IM route are expected to play a pivotal role in encouraging adoption by healthcare professionals and the public.

Furthermore, the consistent success of other vaccines delivered intramuscularly in India helps maintain trust in the safety and effectiveness of this administration method for malaria vaccines.

Download Free Sample Report

Regional Insights

Based on the region, East India dominated the India vaccine Market in 2024. East India, comprising states like West Bengal, Odisha, Bihar, and Assam, is experiencing a significant malaria burden, making it a key region for the malaria vaccine market. These states are known for having high transmission rates of malaria, with large populations living in areas prone to endemic transmission. The prevalence of malaria in these regions, particularly among vulnerable populations such as children and pregnant women, has made it a priority for both government and public health organizations to implement effective prevention strategies, including vaccination.

The demand for malaria vaccines is therefore high in East India, where targeted interventions are necessary to control and reduce malaria incidence. The geographical factors and environmental conditions in these states, such as monsoons and high humidity, create ideal breeding grounds for malaria-carrying mosquitoes, exacerbating the disease burden and increasing the urgency of vaccination programs. Consequently, East India’s substantial malaria cases have made it the dominant market for malaria vaccines in the country, driving efforts to prioritize vaccine distribution and ensure timely access.

Recent Developments

• In September 2025, the ICMR licensed the AdFalciVax technology to five prominent Indian pharmaceutical companies: Indian Immunologicals Limited, TechInvention Lifecare Private Limited, Panacea Biotec Limited, Biological E Limited, and Zydus Lifesciences. This non-exclusive agreement allows these companies to manufacture the vaccine, scale up production, and conduct further clinical trials, paving the way for its eventual commercialization.
• In July 2025, the Indian Council of Medical Research (ICMR) announced the development of AdFalciVax, India's first indigenous multi-stage malaria vaccine. Developed by ICMR's Regional Medical Research Centre in Bhubaneswar, this vaccine is designed to target two critical life stages of the Plasmodium falciparum parasite, the deadliest malaria strain. Unlike existing vaccines, AdFalciVax aims to not only protect against infection but also to interrupt community transmission by targeting the parasite's sexual stage.
• In May 2024, Serum Institute of India, the world’s largest manufacturer of vaccines by number of doses, marks a significant milestone with the shipment of its first set of R21/Matrix-M™ malaria vaccine to Africa. The initial shipment will be sent to the Central African Republic (CAR), followed by other African countries such as South Sudan and Democratic Republic of Congo in the next coming days. In total, 1,63,800 doses of the R21/Matrix-M™ malaria vaccine have been specifically allocated for the CAR region, out of which only 43,200 doses will be dispatched today from Serum Institute of India’s facility.
• In June 2023, the India Health Fund (IHF), which is a funding initiative by Tata Trusts, announced its support for the two platform tools developed by Ameliorate Biotech Pvt Ltd and Medprime Technologies. The tools are a fever panel to detect chikungunya, dengue, malaria, and microscope-agnostic AI-enabled diagnosis software that is applicable across diseases.

Key Market Players

• Gennova Biopharmaceuticals Ltd
• Zydus Group
• Serum Institute of India Private Limited
• Bharat Biotech International Limited
• Indian Immunologicals Limited, Inc.
• Panacea Biotec
• Mynvax
• Cadila Pharmaceuticals
• Biological E Limited
• Sanofi Pasteurs Health

Report Scope:

In this report, India Malaria Vaccine Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

·         India Malaria Vaccine Market, By Vaccine Type:

o    Pre-Erythrocytic

o    Erythrocytic

o    Multi-antigen

o    Others

·         India Malaria Vaccine Market, By Route of Administration:

o    Intramuscular

o    Subcutaneous

o    Intradermal

o    Others

·         India Malaria Vaccine Market, By Region:

o    North India

o    South India

o    East India

o    West India

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present India Malaria Vaccine Market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

India Malaria Vaccine Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]